A retrospective cohort study to investigate the initiation and persistence of dual antiplatelet treatment after acute coronary syndrome in a Finnish setting – THALIA

Study identification

• EU PAS number:
  EUPAS6161
• Study ID:
  47383
• Official title and acronym:
  A retrospective cohort study to investigate the initiation and persistence of dual antiplatelet treatment after acute coronary syndrome in a Finnish setting – THALIA
• DARWIN EU® study:
  No
• Study countries:
  Finland
• Study description:
  Myocardial infarction affects about 5000 new patients in Finland every year. Approximately 20% of these patients die within one year after the event. Dual antiplatelet treatment (DAPT) with low dose acetylsalicylic acid and oral antiplatelet is recommended for patients with acute coronary syndromes. Guidelines recommend DAPT inhibition to be maintained up to over 12 months unless contraindications are present. New oral antiplatelets (OAP) have recently been introduced in the market in the Nordic countries. It is not known how the patient selection for different DAPT treatments and no-DAPT treatment happen. Neither are the persistence of OAP treatments, switch patterns between different OAP treatments, nor patient adherence to OAP treatments understood. The main objective of this study is to characterize and describe the patients treated with DAPT vs. non-DAPT treated patients, and the switch patterns and discontinuation rates of DAPT treatments. Approximately 200 000 patients discharged from Finnish hospitals following admission for unstable angina pectoris or myocardial infarction in 2009-2013 will be studied by using data from nationwide patient registers.
• Study status:
  Finalised

Research institutions and networks

Institutions

IQVIA

United Kingdom

Study timelines

Date when funding contract was signed

Actual: 23/01/2014

Study start date

Planned: 04/08/2014

Actual: 07/10/2014

Data analysis start date

Planned: 01/05/2015

Actual: 18/05/2015

Date of final study report

Planned: 29/04/2016

Actual: 15/10/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca Nordic Baltic

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable